Table 3.

Treatment pattern, categorized by HR status and incidence period

HER2 + total	N	HER2-targeted	ET	CT
		%	%	%
1st line
2008–2012	256	62	24	14
2013–2017	237	69	27	4
2nd line
2008–2012	189	70	21	9
2013–2017	164	70	23	7
3rd line
2008–2012	134	67	19	15
2013–2017	99	73	21	6
1st line
2008–2012	168	53	36	11
2013–2017	162	58	38	4
2nd line
2008–2012	134	66	30	4
2013–2017	123	64	29	7
3rd line
2008–2012	102	61	24	15
2013–2017	80	69	25	6

HR-/HER2 +	N	HER2-targeted	ETa	CT
		%	%	%
1st line
2008–2012	88	80	1	19
2013–2017	75	93	3	4
2nd line
2008–2012	55	80	0	20
2013–2017	41	90	5	5
3rd line
2008–2012	32	81	0	19
2013–2017	19	90	5	5

CT chemotherapy, ET endocrine therapy, HR hormone receptor, HER2 human epidermal growth factor receptor

^aIncludes 3 patients with HR + primary breast tumor